IC TIP UPDATES:
Good news for AstraZeneca (AZN) and its US peer Merck (US:MRK). The US regulator has given Lynparza - the ovarian cancer drug sold by both companies - the green light for expanded use in patients with a recurrent form of the disease who have responded to platinum-based chemotherapy. It also approved a new oral tablet form of the medicine. We remain buyers of both AZN and MRK. Buy.